Arch Biopartners Announces Start of Phase I Human Trial for Metablok
June 19, 2019 07:20 ET
|
Arch Biopartners
TORONTO, June 19, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has initiated the Phase I human trial for...
Arch Biopartners Closes Convertible Note Financing
May 22, 2019 17:01 ET
|
Arch Biopartners
TORONTO, May 22, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has closed the non-brokered, unsecured convertible note...
Arch Biopartners Arranges Convertible Note Financing
May 17, 2019 07:00 ET
|
Arch Biopartners
TORONTO, May 17, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has arranged a non-brokered, unsecured convertible note...
Arch Biopartners Awarded NRC-IRAP Funding to Further Develop Metablok Drug Program
February 07, 2019 08:00 ET
|
Arch Biopartners
TORONTO, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced that the National Research Council – Industrial...
Arch Biopartners Closes Convertible Note Financing
January 29, 2019 08:46 ET
|
Arch Biopartners
TORONTO, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has closed the non-brokered, unsecured convertible note...
Arch Biopartners Arranges Convertible Note Financing
January 24, 2019 08:43 ET
|
Arch Biopartners
TORONTO, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has arranged a non-brokered, unsecured convertible note...
Arch Biopartners Forms New Subsidiary to Pursue a Phase I Trial in Australia for Metablok (LSALT Peptide)
December 11, 2018 08:02 ET
|
Arch Biopartners
TORONTO, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has formed a 100% owned subsidiary in Australia, named...
Arch Biopartners Provides Toxicology Update for Metablok
October 29, 2018 09:00 ET
|
Arch Biopartners
TORONTO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF) today provided an update on the general results from toxicology and...
Arch Biopartners Receives $332,750 From the Exercise of Warrants
June 26, 2018 09:03 ET
|
Arch Biopartners
TORONTO, June 26, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners, Inc., (Arch or the Company) (TSX-V:ARCH) (OTCQB:ACHFF) a portfolio-based biotechnology company, today announced that it received net...
Arch Biopartners Engages Nucro-Technics To Complete Toxicology Studies To Support Investigational New Drug Application For Metablok
May 22, 2018 09:11 ET
|
Arch Biopartners
TORONTO, May 22, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners, Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCQB:ACHFF) a portfolio-based biotechnology company, today announced it has engaged...